Lakefront Biotherapeutics (LKFT) Stock Forecast & Price Target

Lakefront Biotherapeutics is viewed favorably because gamgertamig appears to be a differentiated BCMA/CD3 bispecific with rapid, deep B-cell depletion, durable remissions, and very low CRS risk, which could make it more attractive than CAR-T approaches in rare autoimmune diseases. The company also offers substantial balance-sheet support, with expected end-2026 cash of €2B, implying a negative €180M enterprise value at current levels and leaving about €1.6B after projected spending before first approval, while the cell therapy wind-down and tax/inbound royalty benefits point toward cash flow positivity by YE26. Visibility into value-creating catalysts is improving through dose-ranging data expected by YE-'26 and registrational studies in 2027, and management believes the initial indications could support about $4B in worldwide sales and up to $885M in annual royalties.

Lakefront Biotherapeutics is viewed negatively because its lead asset '3667 failed in SLE at both the 32-week primary endpoint and 48-week secondary endpoint, forcing the company to halt development in lupus and rely on uncertain strategic options rather than a proven path forward. The remaining story is dominated by gamgertamig, but limited quantitative data to date, the need to optimize dosing to reduce CRS while preserving efficacy, and intense competition from other BCMAxCD3 bispecifics make it difficult to underwrite meaningful fundamental value. More broadly, the company must still build a novel pipeline with competitively priced assets, while the Ouro preclinical assets and any broader contribution remain largely unproven until 2027+ and could leave the shares vulnerable if commercial opportunity is limited.